IQ-AI, Ltd.

IQ-AI, Ltd.

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI News & Announcements
  • Total Voting Rights
 

BLOG

IQ-AI
Monday, 28 February 2022 / Published in IQ-AI News & Announcements

Total Voting Rights

/**/
RNS Number : 0358D
IQ-AI Limited
28 February 2022
 

28 February 2022

IQ-AI Ltd

(“IQ-AI” or the “Company”)

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 182,621,390.

 

This figure of 182,621,390 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

 

The Directors of the Company accept responsibility for the contents of this announcement

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source
  • Tweet

What you can read next

Imaging Biometrics Announces Channel Partnership
Notice of AGM
Imaging Biometrics software on aycan workstation

Recent Posts

  • IQ-AI shares cease trading on the OTCQB

    /**/ RNS Number : 9599M IQ-AI Limited 19 Septem...
  • Reduced Gadolinium Approach Validated’

    /**/ RNS Number : 7871L IQ-AI Limited 08 Septem...
  • Update on Collaboration Agreement with Mayo Clinic

    /**/ RNS Number : 8096J IQ-AI Limited 18 August...
  • IB & GE HealthCare Enter into Commercial Agreement

    /**/ RNS Number : 8077J IQ-AI Limited 18 August...
  • Half-year Report

    /**/ RNS Number : 5460J IQ-AI Limited 17 August...
  • Policies
  • Investor Information

iq-ai@imagingbiometrics.com

P. O. Box 264
Forum 4, Grenville Street
St Helier, Jersey, Channel Islands
JE4 8TQ

Copyright © 2015-2023 IQ-AI. All Rights Reserved
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT